| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1998;65:1540-1544
© 1998 The Society of Thoracic Surgeons
a Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
b Angiogenesis Research Center, Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
c Department of Radiology at Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Address reprint requests to Dr Sellke, Division of Cardiothoracic Surgery, Beth Israel Deaconess Medical Center, East Campus, Dana 905, 330 Brookline Ave, Boston, MA 02215
e-mail: (fsellke{at}bidmc.harvard.edu)
Presented at the Thirty-fourth Annual Meeting of The Society of Thoracic Surgeons, New Orleans, LA, Jan 26–28, 1998.
Background. Patients not amenable to complete myocardial revascularization by conventional methods present a difficult clinical problem. Here we present the early results and technical considerations of the administration of basic fibroblast growth factor for the induction of collateral growth using heparin-alginate slow-release devices in patients undergoing coronary artery bypass grafting.
Methods. Eight patients were enrolled. Patients were candidates if they had at least one graftable obstructed coronary artery and at least one major arterial distribution not amenable to revascularization, a serum creatinine level less than 3 mg/dL, ejection fraction greater than 0.20, and estimated operative mortality of less than 25%. During conventional coronary artery bypass grafting, 10 heparin-alginate devices, each containing either 1 µg or 10 µg of basic fibroblast growth factor, were implanted in the epicardial fat in multiple regions of the unrevascularizable territory and also in the distal distribution of a grafted or patent artery.
Results. There was no mortality and no evidence of renal, hematologic, or hepatic toxicity during follow-up. Three months after the operation, all patients remain free of angina. Seven patients were examined with stress perfusion scans. Three patients had clear enhancement of perfusion to the unrevascularized myocardium, 1 patient had a new fixed defect, and 3 had minimal overall change but had evidence of new small, fixed perfusion defects. Seven patients had improved or similar myocardial contractile function (ejection fraction at 3-month follow-up = 0.53 ± 0.22 versus 0.47 ± 0.14 preoperatively). One patient suffered a perioperative myocardial infarction in the area of basic fibroblast growth factor administration.
Conclusions. This preliminary study demonstrates the safety and technical feasibility of therapeutic angiogenesis with basic fibroblast growth factor delivered by heparin-alginate slow-release devices. Further studies examining the safety, clinical efficacy, and long-term results are ongoing.
This article has been cited by other articles:
|
|
 |
|
  M. Boodhwani, P. Voisine, M. Ruel, N. R. Sodha, J. Feng, S.-H. Xu, C. Bianchi, and F. W. Sellke Comparison of vascular endothelial growth factor and fibroblast growth factor-2 in a swine model of endothelial dysfunction Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 645 - 650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Lu, X. Xu, M. Zhang, R. Cao, E. Brakenhielm, C. Li, H. Lin, G. Yao, H. Sun, L. Qi, et al. Combinatorial protein therapy of angiogenic and arteriogenic factors remarkably improves collaterogenesis and cardiac function in pigs PNAS, July 17, 2007; 104(29): 12140 - 12145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Stamatovic, R. F. Keep, M. Mostarica-Stojkovic, and A. V. Andjelkovic CCL2 Regulates Angiogenesis via Activation of Ets-1 Transcription Factor J. Immunol., August 15, 2006; 177(4): 2651 - 2661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. U. Lee, J. J. Wykrzykowska, and R. J. Laham Angiogenesis: Bench to Bedside, Have We Learned Anything? Toxicol Pathol, January 1, 2006; 34(1): 3 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sirivella, I. Gielchinsky, and V. Parsonnet Results of Coronary Artery Endarterectomy and Coronary Artery Bypass Grafting for Diffuse Coronary Artery Disease Ann. Thorac. Surg., November 1, 2005; 80(5): 1738 - 1744. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tsutsumi and D. W. Losordo Double Face of VEGF Circulation, August 30, 2005; 112(9): 1248 - 1250. [Full Text] [PDF]
|
|
|
|
|
|
R. Tiruvoipati, M. Loubani, M. Lencioni, S. Ghosh, P. W. Jones, and R. L. Patel Coronary Endarterectomy: Impact on Morbidity and Mortality When Combined With Coronary Artery Bypass Surgery Ann. Thorac. Surg., June 1, 2005; 79(6): 1999 - 2003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J Teng, K. Lachapelle, and R. C. Chiu Reappraisal of Recent Clinical Trials of Angiogenic Therapy in Myocardial Ischemia Asian Cardiovasc Thorac Ann, March 1, 2005; 13(1): 90 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Byrne, A. N. Karavas, T. Gudbjartson, M. Leacche, J. D. Rawn, G. S. Couper, R. J. Rizzo, L. H. Cohn, and S. F. Aranki Left anterior descending coronary endarterectomy: Early and late results in 196 consecutive patients Ann. Thorac. Surg., September 1, 2004; 78(3): 867 - 873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Losordo and S. Dimmeler Therapeutic Angiogenesis and Vasculogenesis for Ischemic Disease: Part I: Angiogenic Cytokines Circulation, June 1, 2004; 109(21): 2487 - 2491. [Full Text] [PDF]
|
|
|
|
 |
|
 M.H. Tayebjee, G.Y.H. Lip, and R.J. MacFadyen Collateralization and the response to obstruction of epicardial coronary arteries QJM, May 1, 2004; 97(5): 259 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-S. Jiang, W. Srisakuldee, F. Soulet, G. Bouche, and E. Kardami Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion Cardiovasc Res, April 1, 2004; 62(1): 154 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sakakibara, K. Tambara, G. Sakaguchi, F. Lu, M. Yamamoto, K. Nishimura, Y. Tabata, and M. Komeda Toward surgical angiogenesis using slow-released basic fibroblast growth factor Eur. J. Cardiothorac. Surg., July 1, 2003; 24(1): 105 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Hughes, M. J. Post, M. Simons, and B. H. Annex Translational Physiology: Porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis J Appl Physiol, May 1, 2003; 94(5): 1689 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nishida, T.-S. Li, K. Hirata, M. Yano, M. Matsuzaki, and K. Hamano Improvement of cardiac function by bone marrow cell implantation in a rat hypoperfusion heart model Ann. Thorac. Surg., March 1, 2003; 75(3): 768 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Zakine, E. Martinod, P. Fornes, M. Sapoval, D. Barritault, A. F. Carpentier, and J. C. Chachques Growth factors improve latissimus dorsi muscle vascularization and trophicity after cardiomyoplasty Ann. Thorac. Surg., February 1, 2003; 75(2): 549 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. W. Sellke and M. Ruel Vascular growth factors and angiogenesis in cardiac surgery Ann. Thorac. Surg., February 1, 2003; 75(2): S685 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ruel, R. A. Kelly, and F. W. Sellke Therapeutic Angiogenesis, Transmyocardial Laser Revascularization, and Cell Therapy Card. Surg. Adult, January 1, 2003; 2(2003): 715 - 750. [Full Text]
|
|
|
|
|
|
K. A. Detillieux, F. Sheikh, E. Kardami, and P. A. Cattini Biological activities of fibroblast growth factor-2 in the adult myocardium Cardiovasc Res, January 1, 2003; 57(1): 8 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ruel, R. J. Laham, J. A. Parker, M. J. Post, J. A. Ware, M. Simons, and F. W. Sellke Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein J. Thorac. Cardiovasc. Surg., July 1, 2002; 124(1): 28 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Hughes, S. S. Biswas, B. Yin, D. V. Baklanov, B. H. Annex, R. E. Coleman, T. R. DeGrado, C. K. Landolfo, K. P. Landolfo, and J. E. Lowe A comparison of mechanical and laser transmyocardial revascularization for induction of angiogenesis and arteriogenesis in chronically ischemic myocardium J. Am. Coll. Cardiol., April 3, 2002; 39(7): 1220 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hamano, T.-S. Li, T. Kobayashi, K. Hirata, M. Yano, M. Kohno, and M. Matsuzaki Therapeutic angiogenesis induced by local autologous bone marrow cell implantation Ann. Thorac. Surg., April 1, 2002; 73(4): 1210 - 1215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Freedman and J. M. Isner Therapeutic Angiogenesis for Coronary Artery Disease Ann Intern Med, January 1, 2002; 136(1): 54 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Seiler, T. Pohl, K. Wustmann, D. Hutter, P.-A. Nicolet, S. Windecker, F. R. Eberli, and B. Meier Promotion of Collateral Growth by Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Coronary Artery Disease: A Randomized, Double-Blind, Placebo-Controlled Study Circulation, October 23, 2001; 104(17): 2012 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Azrin Angiogenesis, protein and gene delivery Br. Med. Bull., October 1, 2001; 59(1): 211 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Tabibiazar and S.G Rockson Angiogenesis and the ischaemic heart Eur. Heart J., June 1, 2001; 22(11): 903 - 918. [PDF]
|
|
|
|
 |
|
 N.M. Siafakas, M. Jordan, H. Wagner, E.C. Breen, H. Benoit, and P.D. Wagner Diaphragmatic angiogenic growth factor mRNA responses to increased ventilation caused by hypoxia and hypercapnia Eur. Respir. J., April 1, 2001; 17(4): 681 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Epstein, S. Fuchs, Y. F. Zhou, R. Baffour, and R. Kornowski Therapeutic interventions for enhancing collateral development by administration of growth factors: basic principles, early results and potential hazards Cardiovasc Res, February 16, 2001; 49(3): 532 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Kiesz, P. Buszman, J. L. Martin, E. Deutsch, M. M. Rozek, E. Gaszewska, M. Rewicki, P. Seweryniak, M. Kosmider, and M. Tendera Local Delivery of Enoxaparin to Decrease Restenosis After Stenting: Results of Initial Multicenter Trial : Polish-American Local Lovenox NIR Assessment Study (The POLONIA Study) Circulation, January 2, 2001; 103(1): 26 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Pantely and J. M. Porter Therapeutic angiogenesis: time for the next phase J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1245 - 1247. [Full Text] [PDF]
|
|
|
|
|
|
R. Miraliakbari, N. A. Francalancia, R. M. Lust, J. A. Gerardo, P. C. Ng, Y. S. Sun, and W. R. Chitwood Jr Differences in myocardial and peripheral VEGF and KDR levels after acute ischemia Ann. Thorac. Surg., June 1, 2000; 69(6): 1750 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kawasuji, H. Nagamine, M. Ikeda, N. Sakakibara, H. Takemura, S. Fujii, and Y. Watanabe Therapeutic angiogenesis with intramyocardial administration of basic fibroblast growth factor Ann. Thorac. Surg., April 1, 2000; 69(4): 1155 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Kerbel Tumor angiogenesis: past, present and the near future Carcinogenesis, March 1, 2000; 21(3): 505 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Stefanec Endothelial Apoptosis: Could It Have a Role in the Pathogenesis and Treatment of Disease? Chest, March 1, 2000; 117(3): 841 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fujita Heparin and angiogenic therapy Eur. Heart J., February 2, 2000; 21(4): 270 - 274. [PDF]
|
|
|
|
|
|
R. J. Laham, F. W. Sellke, E. R. Edelman, J. D. Pearlman, J. A. Ware, D. L. Brown, J. P. Gold, and M. Simons Local Perivascular Delivery of Basic Fibroblast Growth Factor in Patients Undergoing Coronary Bypass Surgery : Results of a Phase I Randomized, Double-Blind, Placebo-Controlled Trial Circulation, November 2, 1999; 100(18): 1865 - 1871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Sundt III, C. J. Camillo, E. N. Mendeloff, H. B. Barner, and W. A. Gay Jr Reappraisal of coronary endarterectomy for the treatment of diffuse coronary artery disease Ann. Thorac. Surg., October 1, 1999; 68(4): 1272 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. F. Symes, D. W. Losordo, P. R. Vale, K. G. Lathi, D. D. Esakof, M. Mayskiy, and J. M. Isner Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease Ann. Thorac. Surg., September 1, 1999; 68(3): 830 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R Kersten, P. S Pagel, W. M Chilian, and D. C Warltier Multifactorial basis for coronary collateralization: a complex adaptive response to ischemia Cardiovasc Res, July 1, 1999; 43(1): 44 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D Henry Science, medicine, and the future: Therapeutic angiogenesis BMJ, June 5, 1999; 318(7197): 1536 - 1539. [Full Text]
|
|
|
|
 |
|
 C. Metais, J. Li, J. Li, M. Simons, and F. W. Sellke Effects of coronary artery disease on expression and microvascular response to VEGF Am J Physiol Heart Circ Physiol, October 1, 1998; 275(4): H1411 - H1418. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
